SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-expected third-quarter report and managements upbeat 2027 outlook have driven CLFs sharp rally, with bullish traders focused on improved steel pricing and possible short covering. Others question whether the outlook can overcome the companys debt and execution concerns, and some view the move as a sell-the-news bounce.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade to Buy after a sharp selloff fueled hopes of a rebound, but traders debated whether the upgrade could overcome ongoing financing concerns, especially as the rally faded. Bulls point to AI demand, customer commitments and Nvidias support, while bears remain focused on CoreWeaves heavy debt burden and borrowing costs.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

The FDAs early expansion of ANKTIVA plus BCG to papillary-only BCG-unresponsive bladder cancer, alongside long-term data showing durable responses, is driving discussion about a larger patient market and future sales. Traders are puzzled by the share-price decline despite the positive developments, debating a sell-the-news reaction and broader biotech weakness versus unverified claims of short-selling or options-related pressure.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are under heavy pressure amid IPO lockup-related selling concerns and a broader AI and semiconductor pullback, with traders also questioning the companys valuation, growth, and ability to scale. Bears expect further downside as more shares become eligible for sale, while bulls view the selloff as excessive and are averaging in.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are under pressure amid a sharp pullback, with traders pointing to repeated insider sales and a reported DBS downgrade as potential reasons for the weakness; some also cite broader Indonesia and Southeast Asia market concerns. Bulls argue the selling was planned and the business remains strong, while bears see insider selling and weak price action as warning signs.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons advance is drawing attention after Morgan Stanley named it a top pick, citing AWS growth, AI opportunities and warehouse automation as potential catalysts. Traders are broadly bullish on the move, though some remain cautious about heavy AI spending and whether the shares can sustain gains ahead of earnings.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares are surging after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, supporting a planned FDA resubmission. Traders are broadly reacting positively, while debating short-squeeze potential and flagging dizziness and sharp price swings as concerns.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

Sharp post-IPO selling and volatile trading dominate the discussion, with traders pointing to lockup-related supply, bearish analyst coverage, and weakness across nuclear stocks as possible pressures. Bulls are treating the pullback as an opportunity, citing Amazons backing and X-energys potential role in meeting future data-center power demand, while others stress that reactor commercialization remains years away.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a sharp selloff alongside other AI neocloud stocks, as traders debate financing costs and whether the sectors growth can justify its heavy capital needs. Some see the rebound and analyst support as a buying opportunity, while others call it a short-lived bounce and expect more pressure.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on the FDA-cleared expansion of Alpha Taus REGAIN trial for recurrent glioblastoma and anticipated clinical data at the SNO meeting. Traders are bullish on early tumor-control findings and the broader pipeline, though some note the evidence comes from a small initial cohort.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPLPR NewswireNEW...

REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky

REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit...

REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026

REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026 REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026PR NewswireNEW YORK, Sept. 24...

REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm

REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the FirmPR NewswireNEW YORK, Sept. 23, 2026...

REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff Deadline for Information About Recovering Their Losses

REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff Deadline for Information About Recovering Their Losses REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff...

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallStPR NewswireNEW YORK, Sept. 17, 2026 A chronology of...

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPLPR NewswireNEW YORK, Sept. 16, 2026 Replimune...

REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinsky

Levi & Korsinsky, LLP alerts investors in Replimune Group, Inc. (NASDAQ: REPL) of a pending securities class action on behalf of purchasers between October 20, 2025 and April 10, 2026. Check if you might be eligible to recover your investment losses. You may also contact Joseph E. Levi, Esq. at...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today? 

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>J.M. Smucker climbed to nearly a three-year high of $134.85 after the company posted better-than-expected fiscal 2027 first-quarter results.&nbsp;</li><li>JPMorgan kept an ‘Overweight’ rating on Replimune and raised its price target to $21 from $20.&nbsp;</li><li>NeoGenomics secured expanded Medicare coverage for its RaDaR ST liquid biopsy test.&nbsp;</li></ul><p>J.M. Smucker Co. (SJM), Replimune Group (REPL) and NeoGenomics (NEO) hit fresh 52-week highs on Wednesday, fueled by company-specific catalysts. Improving volumes at Smucker, clinical momentum at Replimune and Medicare coverage for NeoGenomics’ cancer test gave investors fresh reasons to buy.&nbsp;</p><p>J.M. Smucker and NeoGenomics stocks gained over 4% and 3%, while Replimune stock climbed 0.5%.&nbsp;</p><h2 class="st-heading-2">J.M.&nbsp;Smucker Gains On Improving Volumes</h2><p><a href="https://stocktwits.com/symbol/SJM">J.M. Smucker stock</a> reached nearly a three-year high of $134.85 after the packaged-food company delivered stronger-than-expected first-quarter fiscal 2027 results. The performance prompted BTIG to increase its price target to $150 from $130 while keeping a ‘Buy’ rating.</p><p>The key signal for investors was a recovery in underlying product volumes. With Hostess excluded, each of Smucker’s operating businesses posted volume gains during the quarter. The company’s Q2 revenue of $2.2 billion and earnings of $3.24 both exceeded analysts' consensus expectations of $2.1 billion and $2.2 per share, respectively, according to Fiscal Ai data.&nbsp;</p><p>On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory.&nbsp;</p><h2 class="st-heading-2">Replimune Builds On Clinical Momentum</h2><p><a href="https://stocktwits.com/symbol/REPL">Replimune stock</a> climbed to an annual high of $15.99 as investors continued to respond to developments surrounding its cancer-treatment pipeline. JPMorgan raised its price target to $21 from $20 and maintained an ‘Overweight’ rating.</p><p>The firm pointed to support from key opinion leaders for the company’s approach to treating melanoma patients whose disease has stopped responding to PD-1 therapies. Replimune’s Tudriqev program has emerged as an important part of that opportunity as the company advances through major regulatory approvals.</p><p>Retail sentiment around the stock remained in ‘bullish’ territory.&nbsp;</p><h2 class="st-heading-2">NeoGenomics Gets A Reimbursement Boost</h2><p><a href="https://stocktwits.com/symbol/NEO">NeoGenomics stock</a> also reached a new 52-week high of $17.45. The company received a Medicare coverage determination for its RaDaR ST liquid biopsy test, which is designed to help detect minimal residual disease and assess treatment response.</p><p>Medicare reimbursement could make it easier for physicians to include the test in cancer care. The decision could expand NeoGenomics' commercial opportunity by reducing a major hurdle to wider adoption by oncology practices. However, retail sentiment around the stock remained in ‘bearish’ territory.</p><p>So far this year, SJM, REPL and NEO stocks have gained between 33% and 63%.&nbsp;</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anf-stock-is-on-fire-after-strong-q2-why-jefferies-still-sees-18-more-upside/cZY8mnGRJpO">ANF Stock Is On Fire After ‘Strong Q2’ — Why Jefferies Still Sees 18% More Upside</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, a hand holds a smartphone displaying the logo of The J.M. Smucker Company.

Earnings, drug development, and healthcare reimbursement fueled the stock rallies.

Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?

Earnings, drug development, and healthcare reimbursement fueled the stock rallies. 

Neogenomics Inc.

J.M. Smucker Co.

$CRWV

$LKNCY

$REPL

$ZETA

$CRWV, $LKNCY, $REPL, and $ZETA are four of the most searched and talked-about stocks among retail investors this morning. Which are you most bullish on? Drop your reasoning in the comments.

Which of these trending stocks are you most bullish on for the next 12 months - $CRWV, $LKNCY, $REPL, or $ZETA?

Stocktwits

Luckin Coffee Inc - ADR

Zeta Global Holdings Corp

Which of these trending stocks are you most bullish on for the next 12 months - 

Stocktwits Polls

$REPL   This had a good run.  Time to transfer it all over to IOVA that is one is strong in the bio-tech with revenue

Victor Agean

$REPL Just wait for the next ATM update…shares will start showing dilution and then shareholders start dumping again.  It is inevitable.

Jeffrey Whitaker

$REPL we are on track. Take the cheaper shares as a gift. Tutes have loaded. Opportunity of a lifetime. 🚀🚀🚀

¢A$H MON€¥

$REPL Hope you guys loaded the boat when this retraced to the $12s. Tutes are loaded... don't bet against them. 🚀🚀🚀

$REPL released TUDRIQEV, its first oncolytic therapy, now commercially available in the U.S. for advanced melanoma.

jorge .miguel

$REPL The company will start shipping its fda approved drug early next week. $500K per patient.

Senior Vip

$REPL  waiting for this bearish seasonal time period to end, then I plan to load REPL when the time is right...

$REPL | Snapshot 📊🧬 
• Business: Replimune Group, Inc., a clinical-stage biotechnology company developing novel oncolytic immunotherapies (RPx platform / RP1) for solid tumors.   • Financial Health & Pipeline: Recent positive momentum backed by favorable FDA Advisory Committee votes for RP1 in advanced melanoma.• Bias & Conviction: Bullish Recovery | Moderate Conviction (Testing key channel resistance at $13.00 with unusual near-the-money call positioning).   🎯 Key Levels: 
🐂 Bull Trigger: $13.00 / $13.50 
🚀 Targets: $15.00 / $16.11 / $18.00 
🛡️ Support: $12.82 / $10.00 
⚠️ Risk: $8.15 / $6.00   🔥 Options Flow: 
• 🟢 09/25/2026 $13.0 Call ($51.6K Opening Block | +0.46% OTM)   #REPL #biotech #tech #finance #hovdid

Feed

News

Sentiment

Earnings

Fundamentals

Info

REPL Replimune Group Inc

Fundamentals

Latest REPL News